Adma Biologics (ADMA) Operating Leases (2020 - 2025)

Adma Biologics has reported Operating Leases for 6 years, with the latest figure at $6.6 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 22.37% year-over-year to $6.6 million; the trailing twelve-month figure through Dec 2025 stood at $6.6 million (down 22.37% YoY), and the FY2025 full-year result was $6.6 million, down 22.37% from the prior year.
• Operating Leases for Q4 2025 stood at $6.6 million, down from $9.4 million in the prior quarter.
• The five-year high for Operating Leases was $10.9 million in Q2 2022, with the low at $6.6 million in Q4 2025.
• Historically, Operating Leases has averaged $9.1 million across 5 years, with a median of $9.3 million in 2025.
• Annual changes were most pronounced in 2021 — Operating Leases jumped 72.18% — and 2025, when it dropped 22.37%.
• Adma Biologics' Operating Leases stood at $7.5 million in 2021, then surged by 43.44% to $10.7 million in 2022, then declined by 8.64% to $9.8 million in 2023, then dropped by 12.46% to $8.6 million in 2024, then slipped by 22.37% to $6.6 million in 2025.
• The last three Operating Leases figures came in at $6.6 million (Q4 2025), $9.4 million (Q3 2025), and $9.3 million (Q2 2025), per Business Quant data.